Axa S.A. Mirum Pharmaceuticals, Inc. Transaction History

Axa S.A.

$32.2 Billion
Q4 2024

A detailed history of Axa S.A. transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Axa S.A. holds 425,646 shares of MIRM stock, worth $20.2 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

425,646

Previous 426,068 0.1%

Holding current value

$20.2 Million

Previous $16.6 Million 5.92%

% of portfolio

0.05%

Previous 0.05%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$37.85 - $46.65 $15,972 - $19,686	-422 Reduced 0.1%	425,646 $17.6 Million
Q3 2024 Nov 14, 2024	BUY	$33.68 - $44.74 $2,559 - $3,400	76 Added 0.02%	426,068 $16.6 Million
Q2 2024 Feb 25, 2025	BUY	$23.57 - $34.85 $8,155 - $12,058	346 Added 0.08%	425,992 $14.6 Million
Q2 2024 Aug 14, 2024	SELL	$23.57 - $34.85 $3.95 Million - $5.85 Million	-167,794 Reduced 28.26%	425,992 $14.6 Million
Q1 2024 May 15, 2024	BUY	$24.92 - $30.02 $1,819 - $2,191	73 Added 0.01%	593,786 $14.9 Million
Q4 2023 Jul 16, 2024	SELL	$27.14 - $34.93 $1,981 - $2,549	-73 Reduced 0.01%	593,713 $17.5 Million
Q4 2023 Feb 14, 2024	SELL	$27.14 - $34.93 $635,130 - $817,431	-23,402 Reduced 3.79%	593,713 $17.5 Million
Q3 2023 Nov 14, 2023	SELL	$24.63 - $32.85 $1.27 Million - $1.7 Million	-51,760 Reduced 7.74%	617,115 $19.5 Million
Q2 2023 Aug 14, 2023	SELL	$23.51 - $30.09 $5.16 Million - $6.61 Million	-219,679 Reduced 24.72%	668,875 $17.3 Million
Q1 2023 May 15, 2023	SELL	$19.19 - $24.1 $1.11 Million - $1.4 Million	-57,984 Reduced 6.13%	888,554 $21.3 Million
Q4 2022 Feb 14, 2023	BUY	$17.59 - $23.83 $1.55 Million - $2.1 Million	88,327 Added 10.29%	946,538 $18.5 Million
Q3 2022 Feb 14, 2023	SELL	$19.98 - $29.44 $563,196 - $829,854	-28,188 Reduced 3.18%	858,211 $18 Million
Q3 2022 Nov 14, 2022	SELL	$19.98 - $29.44 $563,196 - $829,854	-28,188 Reduced 3.18%	858,211 $18 Million
Q2 2022 Feb 14, 2023	SELL	$18.42 - $27.5 $1.79 Million - $2.68 Million	-97,430 Reduced 9.9%	886,399 $17.2 Million
Q2 2022 Aug 15, 2022	SELL	$18.42 - $27.5 $1.79 Million - $2.68 Million	-97,430 Reduced 9.9%	886,399 $17.2 Million
Q1 2022 Feb 14, 2023	BUY	$15.5 - $23.93 $1.95 Million - $3.01 Million	125,618 Added 14.64%	983,829 $21.7 Million
Q1 2022 May 13, 2022	SELL	$15.5 - $23.93 $135,253 - $208,813	-8,726 Reduced 0.88%	983,829 $21.7 Million
Q4 2021 Feb 14, 2022	BUY	$13.05 - $19.35 $1.83 Million - $2.72 Million	140,383 Added 16.47%	992,555 $15.8 Million
Q3 2021 Nov 15, 2021	BUY	$13.95 - $20.18 $2.66 Million - $3.85 Million	190,580 Added 28.81%	852,172 $17 Million
Q2 2021 Aug 13, 2021	BUY	$15.84 - $20.6 $1.47 Million - $1.91 Million	92,610 Added 16.28%	661,592 $11.4 Million
Q1 2021 May 14, 2021	BUY	$16.29 - $21.92 $4.29 Million - $5.78 Million	263,496 Added 86.25%	568,982 $11.3 Million
Q4 2020 Feb 12, 2021	BUY	$15.75 - $25.45 $1.22 Million - $1.97 Million	77,496 Added 33.99%	305,486 $5.33 Million
Q3 2020 Nov 13, 2020	BUY	$18.4 - $26.59 $1.12 Million - $1.62 Million	60,950 Added 36.49%	227,990 $4.39 Million
Q2 2020 Aug 14, 2020	BUY	$11.51 - $20.97 $118,426 - $215,760	10,289 Added 6.56%	167,040 $3.25 Million
Q1 2020 May 15, 2020	BUY	$9.38 - $23.79 $1.47 Million - $3.73 Million	156,751 New	156,751 $2.2 Million

Others Institutions Holding MIRM

# of Institutions

211

Shares Held

53.8M

Call Options Held

2.6K

Put Options Held

99.7K

View Full List

About Mirum Pharmaceuticals, Inc.

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.75B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

More about MIRM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account